Despite the clinical significance of balanced chromosomal abnormalities (BCAs), their characterization has largely been restricted to cytogenetic resolution. We explored the landscape of BCAs at nucleotide resolution in 273 subjects with a spectrum of congenital anomalies. Whole-genome sequencing revised 93% of karyotypes and demonstrated complexity that was cryptic to karyotyping in 21% of BCAs, highlighting the limitations of conventional cytogenetic approaches. At least 33.9% of BCAs resulted in gene disruption that likely contributed to the developmental phenotype, 5.2% were associated with pathogenic genomic imbalances, and 7.3% disrupted topologically associated domains (TADs) encompassing known syndromic loci. Remarkably, BCA breakpoints in eight subjects altered a single TAD encompassing MEF2C, a known driver of 5q14.3 microdeletion syndrome, resulting in decreased MEF2C expression. We propose that sequence-level resolution dramatically improves prediction of clinical outcomes for balanced rearrangements and provides insight into new pathogenic mechanisms, such as altered regulation due to changes in chromosome topology.
timeframe comparable to those for clinical CMA or karyotyping; however, only a limited number of BCAs have been evaluated so far 7, [10] [11] [12] [13] [14] [15] .
In this study, we explored several fundamental but previously intractable questions regarding de novo BCAs associated with human developmental anomalies, such as the origins of their formation, the genomic properties of the sequences that they disrupt, and the mechanisms by which they can act as dominant pathogenic mutations. We evaluated 273 subjects ascertained on the basis of the presence of a BCA discovered by karyotyping in a proband who presented with a developmental anomaly. We mapped the BCA breakpoints at base-pair resolution and created a framework to interpret their significance based on convergent genomic data sets, including CNV and whole-exome sequencing data in tens of thousands of individuals. We also integrated data from high-resolution maps of chromosomal compartmentalization in the nucleus to predict long-range regulatory effects 16, 17 and confirm these predictions with functional validation. Our findings indicate that formation of BCAs involves a variety of mechanisms, that the end result often reflects substantial complexity invisible to cytogenetic assessment, that BCAs directly disrupt genes likely to contribute to early developmental abnormalities in at least one-third of subjects, and that BCAs can cause long-range regulatory changes due to alterations to the chromosome structure.
RESULTS

Sequencing BCAs demonstrates cryptic complexity
We sequenced DNA from 273 subjects originating from five primary referral sites that collectively engaged over 100 clinical investigators. Subjects harbored a BCA that was detected by karyotyping and presented with varied congenital and/or developmental anomalies. Most subjects were surveyed using large-insert whole-genome sequencing (liWGS or 'jumping libraries'; 83%), with the remainder of subjects analyzed by standard short-insert whole-genome sequencing or BCAs are a class of structural variation involving rearrangement of chromosome structure that alters the orientation or localization of a genomic segment without a concomitant large gain or loss of DNA. This class of variation includes inversions, translocations, excisions/ insertions, and more complex rearrangements consisting of combinations of such events. Cytogenetic studies of unselected newborns and control adult males estimate a prevalence of 0.2-0.5% for BCAs in the general population [1] [2] [3] . By contrast, an approximate fivefold increase in the prevalence of BCAs detected by karyotyping has been reported among subjects with neurodevelopmental disorders, particularly intellectual disability (1.5%) 4 and autism spectrum disorder (ASD; 1.3%) 5 , suggesting that a meaningful fraction of BCAs may represent highly penetrant mutations in these subjects.
Delineating the breakpoints of BCAs, and the genomic regions that they disrupt, has long been a fertile area of new gene discovery and has greatly contributed to annotation of the morbidity map of the human genome [6] [7] [8] . Despite the significance of BCAs in human disease, the clinical detection of this unique class of rearrangements still relies on conventional cytogenetic methods, such as karyotyping, that are limited to microscopic resolution (~3-10 Mb) 9 . The absence of gross genomic imbalances renders BCAs invisible to higher-resolution techniques that currently serve as first-tier diagnostic screens for many developmental anomalies of unknown etiology, including chromosomal microarray (CMA), which can detect microscopic and submicroscopic copy number variants (CNVs), or whole-exome sequencing, which surveys singlenucleotide variants within coding regions. Without access to precise breakpoint localization, clinical interpretation of de novo BCAs has been limited to estimates of an untoward outcome from population cytogenetic studies based solely on the presence of a rearrangement (6.1% of de novo reciprocal translocations, 9.4% for de novo inversions) 9 . We have recently shown that innovations in genomic technologies can efficiently identify BCA breakpoints at nucleotide resolution with a cost and targeted breakpoint sequencing (Online Methods and Supplementary Table 1) . Subjects were preferentially selected with confirmed de novo BCAs on the basis of cytogenetic studies or with rearrangements that segregated with a phenotypic anomaly within a family (72.5% of subjects); however, inheritance information was unavailable for one or both parents in the remaining 27.5% of subjects. Subjects harboring BCAs that were inherited from an unaffected parent were excluded from this study. Of interest, 62.6% of subjects received clinical CMA screening before enrollment to confirm the absence of a pathogenic CNV ( Table 1) . Subjects presented with a spectrum of clinical features: congenital anomalies ranged from organ-specific disorders to multisystem abnormalities, as well as neurodevelopmental conditions such as intellectual disability or ASD ( Table 1) . While no specific phenotypes were prioritized for inclusion (Supplementary Fig. 1 ), neurological defects were the most common feature in the cohort (80.2% of subjects when using digitalized phenotypes from Human Phenome Ontology (HPO) 18 ; Table 1 and Supplementary Table 2) .
We identified breakpoints in 248 of the 273 subjects (90.8%) and restricted all subsequent analyses to these 248 subjects. This success rate was consistent with expectations, as simulation of 1 million breakpoints in the genome suggested that 7.6% of breakpoints were localized within genomic segments that cannot be confidently mapped by short-read sequencing (Supplementary Fig. 2 ). Sequencing identified 876 breakpoints across the genome (Fig. 1a) and revised the breakpoint localization by at least one sub-band in 93% of subjects when compared to the karyotype interpretation (breakpoint positions provided in Supplementary Table 3) . Across all rearrangements, 26% (n = 65) of BCAs were found to be complex (involving three or more breakpoints; Supplementary Figs. 3-65 ), including 5% (n = 13) that were consistent with the phenomena of chromothripsis or chromoplexy (complex reorganization of the chromosomes involving extensive shattering and random ligation of fragments from one or more chromosomes) [19] [20] [21] [22] [23] . The most complex BCA involved 57 breakpoints (Supplementary Fig. 59 ). When analyses were restricted to the 230 subjects for which the karyotype suggested a simple chromosomal exchange, 48 (21%) were determined to harbor complexity that was cryptic to the karyotype, emphasizing the insights that are gained from nucleotide resolution. Across all BCAs, 80.7% resolved to less than 10 kb of total genomic imbalance, although several cases harbored large cryptic imbalances (mostly deletions) of varied impact ( Fig. 1b and Supplementary Table 4) . Notably, only 12.2% had imbalances of >100 kb in this study (9.3% greater than 1 Mb), representing a significantly lower fraction than previous cytogenetic estimates 24 . Genomic imbalances associated with BCAs were larger on average among subjects without CMA prescreening, with 15.5% harboring imbalances >1 Mb versus 5.9% in subjects prescreened by CMA (Fig. 1b and Supplementary Table 4) . The total genomic imbalance generally increased with the number of breakpoints, although there were chromothripsis and chromoplexy events that were essentially balanced (for example, subject NIJ19 involved 13 junctions across five chromosomes that resolved to a final genomic imbalance of only 631 bases).
BCA formation is mediated by multiple molecular mechanisms
Extensive mechanistic studies have been performed on breakpoints of large CNV data sets; however, the limited scale and resolution of BCA studies have precluded similar analyses for balanced rearrangements. Using precise junction sequences from 662 breakpoints, we found that nearly half displayed signatures of blunt-end ligation (45%), presumably driven by non-homologous end joining (NHEJ) (Fig. 1c) . A substantial fraction (29%) involved microhomology of 2-15 bp at the breakpoint junction, indicating that template switching coupled to DNA replication mechanisms such as microhomology-mediated break-induced replication (MMBIR) contribute to a substantial fraction of BCAs 25 . A comparable fraction (25%) of junctions harbored microinsertions of several base pairs, consistent with NHEJ or fork stalling and template switching (FoSTeS) mechanisms (Fig. 1c) . Only nine junctions (1%) contained long stretches of homologous sequences (>100 bp) that would be consistent with homology-mediated repair. This is certainly an underestimate given the limitations of short-read sequencing in capturing rearrangements localized within highly homologous sequences such as segmental duplications or microsatellites. We also compared BCA breakpoint signatures from this study to 8,943 deletion breakpoints identified in 1,092 samples from the 1000 Genomes Project 26 and found that BCA breakpoints were enriched for blunt-end signatures while depleted for microhomology and long homologous sequences in comparison to deletion breakpoints (Supplementary Fig. 66) .
Comparison of the observed breakpoints to 100,000 sets of simulated breakpoints that retained the properties of the observed data set (Online Methods) established nominal enrichment for repeat elements (P = 0.021) and fragile sites (P = 0.043), while there was no significant enrichment for the other genomic features tested ( Supplementary  Fig. 67 ). Incorporating Hi-C interaction data to explore the association between nuclear organization of the chromosomes and BCA formation showed that pairs of loci comprising a BCA breakpoint did not stem from regions with significantly higher contact patterns in the nucleus 17 ; however, these pairs displayed genome-wide interaction Clinical description was converted for all 273 subjects into standardized terms using HPO 18 , which allowed systematic association with broad phenotypic categories for each enrolled subject.
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A r t i c l e s patterns that were more correlated than random pairings (P = 0.046; Supplementary Fig. 68 and Supplementary Note). These results suggest that DNA fragments involved in BCA formation are more likely to be colocalized in the same or neighboring subcompartments before chromosomal reassembly, although at the sample sizes available they did not necessarily harbor increased direct interactions.
BCA breakpoints associated with congenital anomalies are enriched for functionally relevant loci
Although protein-coding sequences represent less than 2% of the human genome, the total genic space in which a structural variation can disrupt a transcript is considerable, as the cumulative coverage of transcribed regions is over 60% from recent annotations 27 . Consistent with this expectation, 67% (589/876) of breakpoints in this study disrupted a gene, and at least one gene was truncated in most BCAs (75%; 186/248), which did not deviate from random expectations (observed n = 408 genes, expected n = 392 ± 20 genes; P = 0.220; Supplementary Fig. 69 ). The properties of the disrupted genes, however, deviated significantly from random breakpoints for several key features, suggesting that the pathogenic impact of BCAs in this cohort is not a consequence of their likelihood to disrupt genes but rather a reflection of the gene(s) that they alter (disrupted genes provided in Supplementary Table 5 ). Epilepsy   CAMTA1  DYRK1A  GRIN2B  MBD5  SCN1A   AUTS2  EFTUD2  EHMT1  FOXP2  NFIX  TAB2  ARIH1  DOPEY1  PRPF40A  SYNCRIP  TCF12  ZBTB20   AHDC1  ARHGAP5  BCL11A CHD7  CHD8 CUL3  FBXO11 FOXP1  IL1RAPL1 MYT1L  NFIA NRXN1 PHIP  TCF4 WAC ZNF292  DST HECTD1 LDB1  NFIB PSD3 SPTBN1   KDM6A,  MEF2C,  NSD1,  PAK3,  SATB2  NALCN 
A r t i c l e s
We observed significant enrichment for disruption of genes highly intolerant to truncating mutations, as defined by two independent groups (P = 0.027 for Petrovski et al. 28 and P = 0.0009 for Samocha et al. 29 ; Fig. 2a) , embryonically expressed genes (P = 0.001) 30 , and genes previously associated with autosomal dominant disorders (P = 0.002) 31 , whereas no enrichment was observed for genes associated with autosomal recessive disorders (P = 0.294; Fig. 2a ) 31 . The strongest enrichment at breakpoints was detected for genes previously associated with developmental disorders (≥2 de novo loss-offunction mutations) as amalgamated from independent data sets (P = 2 × 10 −5 ; Supplementary Table 6 ). Significant enrichment was also observed at breakpoints for FMRP target genes and chromatin remodeling genes 32, 33 , consistent with the association of genes implicated in neurodevelopmental disorders (Fig. 2b) 7,30,34-37 , but not CHD8 target genes 38, 39 . When further incorporating expression data of the developing brain from BrainSpan 40 , truncated genes showed higher expression patterns during early developmental stages than randomly simulated data sets (Supplementary Fig. 70 ). By contrast, there was no significant enrichment of genes associated with schizophrenia 41, 42 or gene sets associated with complex disorders that were considered as negative controls such as type 2 diabetes, cancer, or height. Subgroup analyses showed that most enrichment signals were driven by the predominance of neurological abnormalities among the subjects (Supplementary Fig. 71 ).
BCAs predominantly contribute to developmental anomalies by direct gene truncation
We next asked the fundamental question of how often BCAs represent likely pathogenic mutations that contribute to a subject's abnormal developmental phenotype. We built an interpretation framework using categories comparable to those established by ClinVar and the Deciphering Developmental Disorders (DDD) study 43 ; however, we restricted interpretation of potential clinical relevance to 'pathogenic' or 'likely pathogenic' variants, as detailed below and in Supplementary Table 7 . All other variants were interpreted as variants of unknown significance (VUS; the predicted impact for each BCA is provided in Supplementary Table 8) .
Pathogenic variants. We compared loci disrupted by BCAs to genes that had been robustly associated with dominant developmental disorders (≥3 reported cases with de novo loss-of-function mutations in Online Mendelian Inheritance in Man (OMIM), DDD, and amalgamated large-scale sequencing studies in neurodevelopmental disorders; Supplementary Table 6 and Supplementary Note). In total, 66 subjects (26.6%) harbored pathogenic BCAs that disrupted these previously defined developmental loci either through direct gene disruption or genomic imbalance (Fig. 2c, Table 2 , and Supplementary Table 9 ). In the majority of these subjects (53/66), the rearrangement truncated a high-confidence syndromic locus. These included known drivers of recurrent microdeletion syndromes (for example, SATB2, MBD5, EHMT1, NFIA, and ZBTB20) [44] [45] [46] [47] [48] , loci associated with imprinting disorders (SNURF-SNRPN), and genes well established as highly penetrant loci in developmental disorders (for example, CHD7, CHD8, CDKL5, CUL3, DYRK1A, and GRIN2B), as well as more recently implicated genes such as AHDC1, CTNND2, and WAC [49] [50] [51] . Several genes were disrupted in two or more subjects, further confirming their role in developmental anomalies ( Table 2) . Notably, ten subjects harbored BCAs that disrupted genes associated with dominant disorders for which the expected phenotype was not reported in the proband (for example, cardiovascular defects, childhood or lateonset hearing loss, or neurodegenerative disorder; Supplementary Table 9 ). In these subjects, the rearrangements could represent pleiotropy (disruption of the same locus that can manifest in multiple distinct phenotypes) or incidental findings and were thus interpreted as VUS. In the remaining 13 subjects with pathogenic BCAs (13/66), genomic imbalances at the breakpoints either overlapped with known microdeletion/microduplication syndromes or encompassed a gene associated with a dominant developmental disorder (for example, 12p12.1-p11.22 deletion encompassing SOX5).
Likely pathogenic variants. Each specific rearrangement effectively represents a private event, which is a major challenge for interpretation in genomic studies. To interpret variants as likely pathogenic, we relied on convergent genomic evidence from large-scale data sets, postulating that candidate genes associated with congenital anomalies or early developmental defects would show evidence of intolerance to haploinsufficiency. Thirty-one subjects harbored BCAs that were considered likely pathogenic ( Table 2 and Supplementary Table 10) . In 25 subjects, the rearrangement directly disrupted a gene intolerant to de novo loss-of-function mutations, and in which de novo loss-offunction mutations had previously been reported in isolated cases (1 or 2 subjects, with an additional subject now represented by the BCA in our study; for example, CACNA2D3, ROBO2, and NFIB), some of which had strong biological support for involvement in developmental anomalies (EP400, STXBP5, and NRXN3). There were also several genes disrupted in multiple subjects from the cohort (NPAS3, A r t i c l e s PTPRZ1, and SYNCRIP; Table 2 ). Two subjects had BCAs likely associated with genomic disorders: one involved a 2p21-p13.3 duplication encompassing NRXN1, and the other disrupted the imprinted 11p15 region associated with Silver-Russell syndrome (MIM 180860). In the remaining four subjects with likely pathogenic BCAs, the rearrangement truncated genes that were associated with developmental disorders, yet only activating or missense mutations had previously been reported (for example, CACNA1C and GNB1) 52, 53 , proposing a dosage-sensitive model for these loci. On the basis of these results, we interpreted that 12.5% (31/248) of subjects harbored a BCA that likely contributed to the developmental phenotype by disrupting potentially novel candidate genes or disease mechanisms. Collectively, these data suggest that 39.1% (97/248) of subjects have a phenotype that can at least partially be explained by haploinsufficiency or dosage alteration of an individual gene or locus (Fig. 2c) . Notably, the overall diagnostic yield was significantly higher in subsets of the group, such as among those subjects who harbored de novo or cosegregating BCAs in comparison with subjects for whom inheritance was unknown (Fig. 2d) , or among subjects who had not been screened clinically by CMA before enrollment (Fig. 2e) . Despite these substantial yields, the marked increase in the frequency of BCAs associated with birth defects in comparison to the general population still suggests that alternative mutational mechanisms, other than direct gene disruption, may account for the developmental defects in a fraction of subjects for whom the BCAs were interpreted as VUS.
Positional effects via disruption of long-range regulatory interactions
Clusters of BCA breakpoints within intergenic regions may suggest disruption of strong regulatory elements that contribute to disease manifestation via positional effects. Alternatively, this could reflect recurrent rearrangements due to fragile sites and/or recombination hotspots. To isolate genomic regions in which an unusual number of BCA breakpoints were localized, we partitioned the genome into 1-Mb bins. Remarkably, one genomic segment, localized to 5q14.3, achieved genome-wide significance and harbored breakpoints from eight independent BCAs (P = 8 × 10 −9 ; Fig. 3a) .
All BCA breakpoints from the 5q14.3 cluster mapped to a region overlapping the previously described 5q14.3 microdeletion syndrome for which almost 100 subjects have previously been reported, with MEF2C as the proposed genetic driver (Fig. 3b) [54] [55] [56] [57] [58] [59] [60] . However, there are reported deletions that do not encompass MEF2C (Fig. 3b) , and we now report seven BCAs distal to MEF2C in subjects with comparable phenotypes to those of individuals harboring direct disruption of MEF2C, challenging the hypothesis that direct disruption of MEF2C is a necessary cause of the syndrome. When combining data from the literature, a total of 11 subjects harbor balanced rearrangement breakpoints localized to the same 1-Mb region within 5q14.3 ( Fig. 3b) 14, 54, 59 . One BCA directly disrupted MEF2C, while the remaining ten mapped to intergenic regions distal to MEF2C; none included a breakpoint disrupting a locus of known significance elsewhere in the genome, suggesting that an alternative mechanism to direct gene disruption was operating in the 5q14.3 region. All ten BCAs with intergenic breakpoints were predicted to disrupt a TAD containing MEF2C (Fig. 3b) . TADs are structured chromatin domains of increased interactions that typically define a local regulatory unit bridging regulatory elements together with their target genes 61 . Their disruption by genomic rearrangements can lead to impaired gene regulation and, therefore, disease pathogenesis [62] [63] [64] . Correspondingly, in four subjects who harbored BCA breakpoints up to 860 kb distal to MEF2C, and for whom RNA from lymphoblastoid cell lines (LCLs) was available, MEF2C expression was significantly reduced in comparison to controls (Fig. 3d) . These analyses indicate that alteration of the Brain-expressed enhancers located in the region 79 , loops involving MEF2C (yellow circles) 17 , and CTCF-binding sites (green, forward; red, reverse) are indicated. Multiple pathogenic mechanisms converge on a similar syndrome: (i) multigenic deletions that encompass MEF2C and one or both TAD boundaries (n = 68), (ii) MEF2C-intragenic deletions (n = 12) or other loss-of-function mutations, (iii) deletions that do not encompass MEF2C but disrupt one TAD boundary (n = 13), and (iv) BCAs with breakpoints distal to MEF2C (n = 7 subjects from this study and 3 previously reported subjects) 14, 54, 59 . Gray dashed lines indicate reported TADs 61 . (c) Proposed model of chromatin folding in the region defining a regulatory unit for MEF2C. (d) Significantly decreased expression of MEF2C was observed in subjects harboring BCAs distal to MEF2C in comparison to controls. MEF2C expression was measured by qRT-PCR, with levels normalized against those for three endogenous genes and compared to the average MEF2C expression from 16 age-matched controls (two-sided Wilcoxon rank-sum test: DGAP131, DGAP191, DGAP222, P = 0.0085; DGAP218, P = 0.0160). Individual expression values, medians, and first and third quartiles are shown.
TAD architecture in this genomic disorder region can disrupt normal MEF2C expression. When integrated with existing data, the converging clinical features suggest that multiple distinct mutational mechanisms can result in presentation of 5q14.3 microdeletion syndrome: (i) direct disruption of MEF2C via de novo loss-of-function mutations, (ii) deletions including MEF2C, and (iii) long-range positional effects from deletions and BCAs that do not directly truncate MEF2C yet disrupt its normal function via alteration of the TAD structure (Fig. 3c) . Beyond 5q14.3, three other loci were suggestive of an accumulation of BCA breakpoints (2q33.1, 6q14.3, and 14q12; each containing BCA breakpoints from four independent subjects), although they did not reach genome-wide significance (P = 1 × 10 −4 ; Fig. 3a) . At 2q33.1, one BCA disrupted SATB2, associated with Glass syndrome and recognized as the established driver of the 2q33.1 microdeletion syndrome 7, 46 , while the remaining three rearrangements were predicted to affect long-range interactions between SATB2 and its regulatory elements (Supplementary Fig. 72 ). In the 14q12 cluster, all BCA breakpoints were distal to FOXG1, which has been reported in atypical Rett syndrome [65] [66] [67] [68] . The phenotypes associated with all four of these subjects were highly correlated on the basis of analyses of HPO reported terms (HPO-sim P = 0.006; Online Methods and Supplementary Table 11 ) 69, 70 , and are consistent with the multiple previous reports of subjects with dysregulation of FOXG1 (Supplementary Fig. 73 ) [65] [66] [67] [68] 71 . At 6q14.3, four BCAs were localized in proximity to SYNCRIP, a highly constrained gene in which de novo loss-of-function had been reported in two subjects with neurodevelopmental disorders 72 . In one subject, the BCA directly disrupted SYNCRIP, and another subject harbored a breakpoint distal to SYNCRIP that was part of a cryptic 6q14.3 deletion encompassing the full gene, although the impact of the other two BCAs was unclear owing to their localization to an adjacent contact domain (Supplementary Fig. 74 ). Finally, a systematic screen identified four additional subjects in whom a TAD disruption could represent a positional effect on known syndromic loci associated with a developmental disorder that closely matched the subject's phenotype (PITX2, SLC2A1, SOX9, and SRCAP; Supplementary Figs. 75-77) . In two of these regions, LCLs were available from the corresponding subjects and expression of the proposed driver gene was significantly reduced when compared to controls (SLC2A1 and SRCAP; Supplementary  Figs. 75 and 76) .
Collectively, 7.3% of subjects harbored a BCA predicted to alter long-range regulatory interactions involving an established syndromic locus with comparable phenotype, recurrently involving MEF2C, SATB2, and FOXG1, while an additional four subjects harbored a BCA that may represent long-range positional effects (two confirmed by expression studies). These data suggest that alterations to TAD structures likely represent a significant component of the deleterious impact of genomic rearrangements.
DISCUSSION
This characterization of BCAs at nucleotide resolution offers new insights into their mechanisms of formation, the properties connected to their rearrangement in the nucleus, and a substantial yield of potentially new genes associated with human development. These results also emphasize that neither the mere presence of a BCA in a subject with developmental anomalies nor the number of genes it disrupts (if any) provide sufficient prognostic power, but rather that the properties of the specific genes and regions that are altered are the most informative in predicting resultant phenotypes (Fig. 4) . These data build upon recent studies of genome topology and provide further evidence that alterations to chromosome structure can lead to alternative yet potentially predictable pathogenic mechanisms by changing the long-range regulatory architecture of physical interactions and chromatin looping in the nucleus [62] [63] [64] 69 . The yield of clinically meaningful results in this study was substantial, ranging from 26.6% to 46.4% of subjects evaluated. Nonetheless, the relative enrichment in cytogenetic studies of BCAs from subjects with developmental abnormalities in comparison to controls suggests that there are alternative pathogenic mechanisms associated with de novo chromosomal rearrangements yet to be discovered 4, 5 .
These data provide an initial vantage of the potential utility of emerging data sets that characterize the nuclear organization of chromosomes. They suggest new pathogenic mechanisms by which BCAs may operate, which seem to result from the disruption of long-range interactions between regulatory elements and their target gene [62] [63] [64] 69 . Structural variants can alter DNA topology and contact domains, with potentially dramatic regulatory consequences. TADs cover a substantial fraction of the genome; therefore, the vast majority of structural variation will perturb one of these domains and such perturbation cannot constitute a predictive criterion for pathogenicity per se. However, these data suggest that identification of recurrent disruption of a TAD encompassing a high-confidence locus beyond what is expected by chance, concomitant with strong phenotypic overlap between the carrier of the variant and independent subjects haploinsufficient for the locus and a demonstrated effect on gene expression, may represent a first step toward highlighting putative positional effects in the human genome. There is clearly a need for sensitive and specific tools to predict such positional effects caused by long-range regulatory perturbations and to annotate further the morbidity map of the genome with more expansive KAT6B  CDKL5  AHDC1  NALCN  PDE10A  WAC  IL1RAPL1  NFIX  SCN1A  EFTUD2  NFIA  SOX5  DYRK1A  PHF21A  EHMT1  SATB2  SMS  CHD8  GRIN2B  NRXN1  MYT1L  FOXP2  TCF4  CAMTA1  AUTS2  SPAST  SNRPN  FOXP1  PAK3  CTNND2  KDM6A  MBD5  MEF2C  CUL3  ZBTB20 NOTCH2 Genes disrupted at breakpoints of pathogenic BCAs
Row z score Phenotypes reported in subjects grouped by involved organ Figure 4 Correlations between phenotypes and genes disrupted in subjects harboring pathogenic BCAs. For each gene, the phenotypes reported in the corresponding subject were digitalized using HPO 18 . One tile represents the normalized count of HPO terms belonging to each organ category reported in the subject(s). Genes clustered together when sharing similarly affected organs, from which five groups can be delineated: (i) genes associated with multiple nervous system and craniofacial abnormalities (dark blue); (ii) genes connected to multiple neurological phenotypes (pink); (iii) genes associated with craniofacial abnormalities and a few neurological symptoms (black); (iv) genes associated with skeletal and limb abnormalities and with limited neurological involvement (green); and (v) genes without neurological involvement (light blue).
A r t i c l e s knowledge of these functional interactions. The fraction of BCAs in this study that may be associated with this pathogenic mechanism is therefore just an entrée into their likely significance as a component of the unexplained genetic contribution to human birth defects.
In terms of evaluating diagnostic strategies, this study further highlights limitations of current diagnostic tools such as karyotyping or CMA in detecting and interpreting BCAs 10, [12] [13] [14] [15] . While the capability to visualize chromosomes and detect de novo BCAs by traditional karyotyping represented a critical leap in genetic diagnostics, as exemplified by the seminal population cytogenetic studies performed by our late co-author Dorothy Warburton 73 , the detection of gross chromosomal abnormalities provides limited prognostic capability. Our data demonstrate that karyotyping substantially underestimates complex rearrangements and is almost always revised by at least a sub-band. Karyotyping is also insensitive to genomic imbalances that cannot be directly visualized (~5-10 Mb). By comparison, CMA is generally recommended as a first-tier diagnostic screen given its sensitivity in detecting submicroscopic CNVs, yet it is blind to copy-neutral events such as those described herein. This study provides critical new insights into the fraction of BCAs that can be ascertained by CMA. In comparison to cytogenetic estimates suggesting that up to 40% of BCAs resolved as unbalanced rearrangements and could therefore be ascertained using CMA 24 , whole-genome sequencing in this cohort suggests that, at 100-kb resolution, only about 12% of BCAs involved a genomic imbalance. If we consider only the 102 subjects for whom no CMA was previously performed, this proportion increases to 18.8% at 100-kb resolution and 17.6% at 500-kb resolution, suggesting that 81.2-82.4% of BCAs in this study would be inaccessible to most CMA platforms routinely used in clinical diagnostics. Notably, there is still benefit to an initial CMA screen, as is illustrated by the markedly lower yield of pathogenic BCAs among subjects who had been prescreened by CMA (19-37%) in comparison to those who had not (41-64%; Fig. 2e ), indicating that a fraction of pathogenic variation in these genomes was captured by the CMA prescreen, either in relation to or independent of the BCA.
These data strongly argue for the implementation of technologies capable of detecting both balanced and unbalanced genomic rearrangements. This could be achieved by using a conventional cytogenetic test followed by a reflex whole-genome sequencing analysis when an abnormality is detected, an approach that we have previously demonstrated can provide access to all classes of structural variation in the human genome in a relatively rapid timeframe 11, 74 . Despite the great promise of this approach, it is important to recognize the limitations of massively parallel sequencing in routine cytogenetic practice. This study used large-insert jumping libraries to maximize physical coverage and minimize cost per base of the genome covered. Yet, these analyses failed to identify breakpoints for 9% of the BCAs tested, and our simulations indicate that at large sample sizes we would anticipate ~7-8% of breakpoints to be undetectable by short-read sequencing. As sequencing technologies and analytical capabilities improve, this component of the variant spectrum that is recalcitrant to short-read sequencing will become more tractable to genomic approaches, and the future implementation of long-read sequencing may revolutionize the capacity to survey currently inaccessible segments of the human genome 75, 76 .
In conclusion, these data indicate that de novo BCAs represent a highly penetrant mutational class in human disease and that their delineation can provide prognostic insights not available at current cytogenetic resolution. Although encouraging, this yield does not explain all of the developmental anomalies in this cohort and suggests that additional pathogenic mechanisms await discovery. A meaningful fraction may be attributable to new genes or regulatory alterations, but additional pathogenic mechanisms remain to be explored, such as recessive modes of inheritance, gene fusions, disruption of imprinted regions, enhancer adoption 69, 77 , and more complex oligogenic models. Evaluation of extremely large cohorts will be required to resolve further such mechanisms, and characterization of BCAs in control populations would benefit annotation of the morbidity map of the human genome and interpretation of the biological and clinical consequences of its structural rearrangement.
METhODS
Methods and any associated references are available in the online version of the paper. 
